Kazia Therapeutics is pleased to make its March 2020 newsletter available to investors.
Our CEO, Dr James Garner sat down with Peter Switzer to discuss Kazia’s upcoming value-driving milestones in 2020 and the development of lead program, paxalisib, for Switzer Financial Group’s The CEO Masterclass series.